Clariane and Sooma Medical join forces to accelerate innovation in mental health and neurorehabilitation
Un an après leur rencontre dans le cadre du programme de partenariat du Conseil européen de l’innovation (EIC), Clariane et la medtech finlandaise Sooma concrétisent leur collaboration. Ensemble, ils lancent un pilote européen dans plus de 35 établissements du Groupe afin d’évaluer une technologie de neuromodulation non invasive destinée à accompagner les personnes souffrant notamment de dépression, de douleurs chroniques ou nécessitant une prise en charge en neurorééducation.
From a meeting to a European partnership
In June 2025, Clariane participated in the EIC Corporate Partnership programme, a European Innovation Council initiative aimed at connecting large companies with the most promising European start-ups.
Over the course of discussions between the Clariane and Sooma teams, the Innovation Days held in Milan and then Barcelona, and the work carried out by the Group’s medical experts, what began as a meeting gradually developed into a partnership. A framework agreement was concluded in June 2026, paving the way for the launch of a European pilot.
The partnership is now entering a new phase: a trial period conducted as close as possible to patients and teams.
An innovation tested in Clariane’s facilities
The pilot is now in place in more than 35 Clariane facilities – clinics, mental health facilities and nursing homes – in France, Spain, Italy, Belgium and the Netherlands.
For 18 months, the teams will evaluate how Sooma technology integrates with care pathways, its acceptability to patients and professionals and the conditions needed for a potential wider deployment within the Group. The pilot will also encourage medical teams in different countries to share their experiences, helping to identify the best conditions for implementing this innovative technology.
The clinical challenges addressed by Sooma’s neuromodulation solution are shared across several countries within the Clariane Group, particularly regarding depression, neurorehabilitation and chronic pain. Designing the pilot from the outset as a multi-country initiative allows us to compare implementation conditions, share learnings between medical teams, and better assess the scalability of the technology across our different healthcare environments.
Tech at the Core, Human at heart
Chez Clariane, l’innovation n’a de sens que si elle répond à un besoin concret des patients, des résidents et des professionnels. C’est pourquoi chaque nouvelle solution est évaluée sur le terrain avant d’envisager son déploiement à plus grande échelle.
Le partenariat avec Sooma illustre cette démarche : transformer une innovation européenne prometteuse en une solution concrètement évaluée au plus près des patients et des professionnels, avant d’envisager son déploiement à plus grande échelle.
Au-delà de cette collaboration, ce projet illustre la conviction de Clariane que l’innovation se construit collectivement : en associant les professionnels de santé, les équipes de terrain et les acteurs européens de l’innovation pour développer des solutions répondant aux besoins d’aujourd’hui et de demain.
At Clariane, innovation only makes sense if it meets a concrete need expressed by patients, residents and professionals. This is why we assess each new solution in the field before considering whether to roll it out on a larger scale.
Our partnership with Sooma illustrates this approach: by taking a promising European innovation and working as closely as possible to patients and professionals, we are transforming it into a concretely assessed solution before considering any larger-scale roll-out.
Beyond our partnership, the project demonstrates Clariane’s belief that innovation is built collectively, by bringing together healthcare professionals, field teams and European innovators to develop solutions that meet the needs of today and tomorrow.
